CR20210232A - NUEVOS PÉPTIDOS Y NUEVA COMBINACIÓN DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE PÁNCREAS Y OTROS TIPOS DE CÁNCER (Divisional 2017-0419) - Google Patents

NUEVOS PÉPTIDOS Y NUEVA COMBINACIÓN DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE PÁNCREAS Y OTROS TIPOS DE CÁNCER (Divisional 2017-0419)

Info

Publication number
CR20210232A
CR20210232A CR20210232A CR20210232A CR20210232A CR 20210232 A CR20210232 A CR 20210232A CR 20210232 A CR20210232 A CR 20210232A CR 20210232 A CR20210232 A CR 20210232A CR 20210232 A CR20210232 A CR 20210232A
Authority
CR
Costa Rica
Prior art keywords
peptides
combination
present
tumor
cancers
Prior art date
Application number
CR20210232A
Other languages
English (en)
Inventor
Oliver Schoor
Martina Ott
Andrea Mahr
Toni Weinschenk
Jens Fritsche
Harpreet Singh
Claudia Wagner
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61866862&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20210232(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB201504502A external-priority patent/GB201504502D0/en
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of CR20210232A publication Critical patent/CR20210232A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001174—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)

Abstract

La presente invención se refiere a péptidos, proteínas, ácidos nucleicos y células destinados a la utilización en métodos inmunoterapéuticos. En particular, la presente invención se refiere a la inmunoterapia contra el cáncer. La presente invención se refiere asimismo a epítopos péptidos para linfocitos T asociados a tumores, solos o en combinación con otros péptidos asociados a tumores que, por ejemplo, pueden servir como principios activos farmacéuticos en composiciones vacunales destinadas a estimular respuestas inmunitarias antitumorales, o a estimular ex vivo linfocitos T que después serán transferidos a los pacientes. Los péptidos unidos a moléculas del complejo mayor de histocompatibilidad (MHC), o los péptidos como tales, también pueden ser dianas de anticuerpos, de receptores de linfocitos T solubles, y de otras moléculas de unión.
CR20210232A 2015-03-17 2016-03-17 NUEVOS PÉPTIDOS Y NUEVA COMBINACIÓN DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE PÁNCREAS Y OTROS TIPOS DE CÁNCER (Divisional 2017-0419) CR20210232A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562134253P 2015-03-17 2015-03-17
GB201504502A GB201504502D0 (en) 2015-03-17 2015-03-17 Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
PCT/EP2016/055817 WO2016146751A1 (en) 2015-03-17 2016-03-17 Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers

Publications (1)

Publication Number Publication Date
CR20210232A true CR20210232A (es) 2022-06-24

Family

ID=61866862

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210232A CR20210232A (es) 2015-03-17 2016-03-17 NUEVOS PÉPTIDOS Y NUEVA COMBINACIÓN DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE PÁNCREAS Y OTROS TIPOS DE CÁNCER (Divisional 2017-0419)

Country Status (13)

Country Link
US (14) US10449239B1 (es)
JP (3) JP6990935B2 (es)
AU (1) AU2020220071B2 (es)
CL (5) CL2017002346A1 (es)
CO (1) CO2017009101A2 (es)
CR (1) CR20210232A (es)
HK (1) HK1247842A1 (es)
IL (2) IL254081B (es)
MX (1) MX2022005570A (es)
MY (1) MY190083A (es)
PH (1) PH12017501467A1 (es)
TW (2) TWI755158B (es)
ZA (1) ZA201705219B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016174085A1 (en) * 2015-04-27 2016-11-03 Cancer Research Technology Limited Method for treating cancer
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
CN116355851B (zh) * 2023-03-13 2023-09-08 广州医科大学附属第一医院（广州呼吸中心） 一种来源于人非小细胞肺癌的原代细胞株及其制备方法与应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610031A (en) 1993-10-27 1997-03-11 The General Hospital Corporation B1k chain of laminin and methods of use
US20030064072A9 (en) 1999-03-12 2003-04-03 Rosen Craig A. Nucleic acids, proteins and antibodies
US20020076721A1 (en) 2000-08-07 2002-06-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2003010327A2 (en) 2001-02-21 2003-02-06 Curagen Corporation Novel proteins and nucleic acids encoding same
JP2003321494A (ja) 2002-02-26 2003-11-11 Daiichi Fine Chemical Co Ltd プロｍｍｐ−７の活性化調節方法
AU2003295328A1 (en) 2002-10-02 2004-04-23 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20060252922A1 (en) 2002-12-04 2006-11-09 Macina Roberto A Compositions, splice variants and methods relating to colon specific genes and proteins
SI1760089T1 (sl) 2005-09-05 2009-12-31 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi, ki se veĹľejo na molekule humanega levkocitnega antigena (HLA) razreda I ali II in ustrezno cepivo proti raku
ES2553270T3 (es) 2007-07-27 2015-12-07 Immatics Biotechnologies Gmbh Nuevo epítopo inmunogénico para inmunoterapia
CN103911358B (zh) 2007-07-27 2017-03-01 伊玛提克斯生物技术有限公司 神经元和脑肿瘤的新型免疫疗法
WO2009075883A2 (en) * 2007-12-12 2009-06-18 University Of Georgia Research Foundation, Inc. Glycoprotein cancer biomarker
WO2010021822A2 (en) * 2008-07-30 2010-02-25 The Regents Of The University Of California Discovery of candidate biomarkers of in vivo apoptosis by global profiling of caspase cleavage sites
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
AU2012203810B2 (en) 2011-06-22 2013-12-05 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of bladder cancer
US20140065620A1 (en) 2011-12-29 2014-03-06 Mayo Foundation For Medical Education And Research Nucleic acids for detecting breast cancer
US20150072349A1 (en) * 2012-03-16 2015-03-12 University Health Network Cancer Biomarkers and Methods of Use
EP2806274A1 (en) * 2013-05-24 2014-11-26 AIT Austrian Institute of Technology GmbH Lung cancer diagnostic method and means
TWI777198B (zh) 2013-08-05 2022-09-11 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（七）
GB201423361D0 (en) * 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides

Also Published As

Publication number Publication date
CL2021000624A1 (es) 2021-08-06
HK1247842A1 (zh) 2018-10-05
US10792350B2 (en) 2020-10-06
US10561718B2 (en) 2020-02-18
US20200405830A1 (en) 2020-12-31
US10898561B2 (en) 2021-01-26
JP7478718B2 (ja) 2024-05-07
MY190083A (en) 2022-03-25
US10729755B1 (en) 2020-08-04
CL2018002427A1 (es) 2018-10-12
MX2022005570A (es) 2022-06-09
CL2017002346A1 (es) 2018-03-09
US20210322527A1 (en) 2021-10-21
US20190388530A1 (en) 2019-12-26
US10668138B1 (en) 2020-06-02
US20200316183A1 (en) 2020-10-08
US20230051035A1 (en) 2023-02-16
US11116826B2 (en) 2021-09-14
US20230065320A1 (en) 2023-03-02
US20200147192A1 (en) 2020-05-14
JP6990935B2 (ja) 2022-02-15
AU2020220071A1 (en) 2020-09-03
US20200230222A1 (en) 2020-07-23
US11007257B2 (en) 2021-05-18
IL254081B (en) 2022-06-01
JP2024041860A (ja) 2024-03-27
CO2017009101A2 (es) 2017-11-30
US20230094790A1 (en) 2023-03-30
AU2020220071B2 (en) 2022-06-02
US11007258B2 (en) 2021-05-18
US10449239B1 (en) 2019-10-22
US20190388531A1 (en) 2019-12-26
TWI755157B (zh) 2022-02-11
JP2020120659A (ja) 2020-08-13
IL280879A (en) 2021-04-29
CL2021000623A1 (es) 2021-07-23
CL2020001675A1 (es) 2020-09-25
US20200338175A1 (en) 2020-10-29
TW202124417A (zh) 2021-07-01
US20190314473A1 (en) 2019-10-17
US10576135B2 (en) 2020-03-03
TWI755158B (zh) 2022-02-11
US20200268861A1 (en) 2020-08-27
IL254081A0 (en) 2017-10-31
TW202124428A (zh) 2021-07-01
PH12017501467A1 (en) 2018-01-15
US20210228698A1 (en) 2021-07-29
ZA201705219B (en) 2019-06-26
JP2022046465A (ja) 2022-03-23

Similar Documents

Publication Publication Date Title
PH12018500551A1 (en) Novel peptides and combination of peptides for use in immunotherapy against various cancers
MX2021015933A (es) Peptidos y combinacion de peptidos para usarse en la inmunoterapia contra el cancer de prostata y otros tipos de cancer.
PH12018500848A1 (en) Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers
PH12018500864A1 (en) Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
CR20210233A (es) NUEVOS PÉPTIDOS Y NUEVA COMBINACIÓN DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE PÁNCREAS Y OTROS TIPOS DE CÁNCER (Divisional 2017-0419)
MX2021013147A (es) Peptidos novedosos y combinacion de peptidos para usarse en inmunoterapia contra cancer de ovario y otros canceres.
MX2017017145A (es) Peptidos novedosos y combinacion de peptidos para usarse en inmunoterapia contra cancer de ovario y otros canceres.
MX2018009958A (es) Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el linfoma no hodgkiniano (lnh) y otros tipos de cancer.
MX2018005273A (es) Peptidos y combinacion de peptidos para usarse en la inmunoterapia contra el cancer de mama y otos tipos de cancer.
MX2017012427A (es) Peptidos novedosos y combinacion de peptidos para usarse en inmunoterapia contra diferentes tumores.
MX2018002480A (es) Peptidos novedosos, combinacion de peptidos y soportes para usarse en el tratamiento inmunoterapeutico de varios tipos de cancer.
PH12017502279A1 (en) Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers
PH12018500004A1 (en) Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
MX2018010875A (es) Peptidos novedosos y combinacion de peptidos para usarse en inmunoterapia contra diferentes tumores.
MX2022001319A (es) Peptidos novedosos, combinacion de peptidos y soportes para usarse en el tratamiento inmunoterapeutico de varios tipos de cancer.
MY196837A (en) Novel peptides and combination of peptides for use in immunotherapy against various cancers
MX2022005570A (es) Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el cancer de pancreas y otros tipos de cancer.
PH12018501639A1 (en) Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers